Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Cidara Therapeutics Inc (NASDAQ: CDTX) closed at $105.62 down -4.54% from its previous closing price of $110.64. In other words, the price has decreased by -$4.54 from its previous closing price. On the day, 0.94 million shares were traded. CDTX stock price reached its highest trading level at $110.98 during the session, while it also had its lowest trading level at $105.45.
Ratios:
For a deeper understanding of Cidara Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.45 and its Current Ratio is at 16.45. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, JP Morgan on October 10, 2025, initiated with a Overweight rating and assigned the stock a target price of $200.
On March 12, 2025, Citizens JMP started tracking the stock assigning a Mkt Outperform rating and target price of $46.Citizens JMP initiated its Mkt Outperform rating on March 12, 2025, with a $46 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 11 ’25 when Davarpanah Nicole Negar sold 474 shares for $62.86 per share. The transaction valued at 29,797 led to the insider holds 31,418 shares of the business.
RA CAPITAL MANAGEMENT, L.P. bought 2,272,727 shares of CDTX for $99,999,988 on Jun 26 ’25. The Director now owns 3,365,523 shares after completing the transaction at $44.00 per share. On Jun 02 ’25, another insider, Mineo Chrysa, who serves as the Director of the company, bought 2,270 shares for $21.71 each. As a result, the insider paid 49,281 and bolstered with 2,270 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDTX now has a Market Capitalization of 2678317568 and an Enterprise Value of 2170075392.
Stock Price History:
The Beta on a monthly basis for CDTX is 1.29, which has changed by 8.92287 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, CDTX has reached a high of $121.21, while it has fallen to a 52-week low of $10.14. The 50-Day Moving Average of the stock is 38.35%, while the 200-Day Moving Average is calculated to be 159.74%.
Shares Statistics:
For the past three months, CDTX has traded an average of 760.87K shares per day and 1102250 over the past ten days. A total of 23.23M shares are outstanding, with a floating share count of 19.37M. Insiders hold about 23.61% of the company’s shares, while institutions hold 84.51% stake in the company. Shares short for CDTX as of 1759190400 were 3046157 with a Short Ratio of 4.00, compared to 1756425600 on 2150846. Therefore, it implies a Short% of Shares Outstanding of 3046157 and a Short% of Float of 12.020000999999999.
Earnings Estimates
Investors are keenly observing as 7.0 analysts analyze and rate. The current performance of Cidara Therapeutics Inc (CDTX) in the stock market.The consensus estimate for the next quarter is -$1.49, with high estimates of -$0.82 and low estimates of -$2.03.
Analysts are recommending an EPS of between -$4.0 and -$6.99 for the fiscal current year, implying an average EPS of -$5.99. EPS for the following year is -$8.11, with 7.0 analysts recommending between -$3.9 and -$13.55.
